Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
| Autor: | Chintan J Dedhia, Remya Paulose, Jay Chhablani, Michael W. Stewart, Ahmad M. Mansour |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Retinal Vein Visual acuity genetic structures 03 medical and health sciences 0302 clinical medicine Pro re nata Ophthalmology Edema Occlusion Clinical endpoint Medicine Prospective cohort study Macular edema business.industry ziv-aflibercept Clinical Ophthalmology medicine.disease eye diseases 030104 developmental biology Clinical Trial Report retinal vein occlusion 030221 ophthalmology & optometry sense organs medicine.symptom business cystoid macular edema |
| Zdroj: | Clinical Ophthalmology (Auckland, N.Z.) |
| ISSN: | 1177-5483 |
| Popis: | Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA; 3Department of Ophthalmology, American University of Beirut, 4Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon Aim: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). Methods: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 µm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 µm. The primary endpoint was improvement in mean CMT at 4 months. Secondary endpoints included improvement in mean BCVA, and ocular and systemic safety signals. Results: Nine eyes (five central and four branch RVOs) of nine patients were enrolled. The mean±standard deviation CMT decreased from 604±199 µm at baseline to 319±115 µm (P=0.001) at 1 month and to 351±205 µm (P=0.026) at 4 months. The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits. No safety signals were noted. Conclusion: In this small prospective study, intravitreal ziv-aflibercept significantly improved mean CMT in eyes with persistent or recurrent macular edema due to RVOs. Prospective, randomized trials comparing ziv-aflibercept with standard pharmacotherapy are needed to better define efficacy and safety. Keywords: ziv-aflibercept, retinal vein occlusion, cystoid macular edema |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|